Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology
Group Leader

Shannon Stockton

Vanderbilt University Medical Center Ingram Cancer Center
Instructor of Medicine

My practice is divided between general hematology/oncology and a focused day on breast oncology. I have a background in early phase clinical trials.

 

Group Co-Leader

Keaton Gaffney

Vanderbilt University Medical Center
Breast Center Clinical Pharmacist

I am the Breast Cancer Clinical Pharmacist at Vanderbilt University Medical Center. I have worked in this position for about 2 and half years. I love my job and am always learning something new everyday!